Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


Novel targets for the treatment of relapsing multiple myeloma.

Giuliani N, Accardi F, Marchica V, Dalla Palma B, Storti P, Toscani D, Vicario E, Malavasi F.

Expert Rev Hematol. 2019 Jul;12(7):481-496. doi: 10.1080/17474086.2019.1624158. Epub 2019 Jun 3.


The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged.

Storti P, Agnelli L, Palma BD, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N.

Haematologica. 2019 Oct;104(10):e465-e469. doi: 10.3324/haematol.2018.209999. Epub 2019 Mar 7. No abstract available.


Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.

Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R, Ferretti E, Dalla Palma B, Vicario E, Accardi F, Mancini C, Martella E, Ribatti D, Vacca A, Pistoia V, Giuliani N.

Cancers (Basel). 2019 Mar 6;11(3). pii: E321. doi: 10.3390/cancers11030321.


Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.

Raimondo S, Saieva L, Vicario E, Pucci M, Toscani D, Manno M, Raccosta S, Giuliani N, Alessandro R.

J Hematol Oncol. 2019 Jan 8;12(1):2. doi: 10.1186/s13045-018-0689-y.


Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.

Toscani D, Bolzoni M, Ferretti M, Palumbo C, Giuliani N.

Front Immunol. 2018 Oct 24;9:2467. doi: 10.3389/fimmu.2018.02467. eCollection 2018. Review.


Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis.

Petrusca DN, Toscani D, Wang FM, Park C, Crean CD, Anderson JL, Marino S, Mohammad KS, Zhou D, Silbermann R, Sun Q, Kurihara N, Galson DL, Giuliani N, Roodman GD.

J Hematol Oncol. 2018 Oct 4;11(1):123. doi: 10.1186/s13045-018-0666-5.


Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD.

Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, Giuliani N, Malavasi F.

Oncoimmunology. 2018 May 7;7(8):e1458809. doi: 10.1080/2162402X.2018.1458809. eCollection 2018.


The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.

Bolzoni M, Toscani D, Costa F, Vicario E, Aversa F, Giuliani N.

Immunol Lett. 2019 Jan;205:65-70. doi: 10.1016/j.imlet.2018.04.007. Epub 2018 Apr 24. Review.


Possible targets to treat myeloma-related osteoclastogenesis.

Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N.

Expert Rev Hematol. 2018 Apr;11(4):325-336. doi: 10.1080/17474086.2018.1447921. Epub 2018 Mar 9. Review.


Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

Dalla Palma B, Marchica V, Pedrazzoni M, Accardi F, Notarfranchi L, Goldoni M, De Luca F, Costa F, Storti P, Toscani D, Sammarelli G, Bonomini S, Aversa F, Giuliani N.

Br J Haematol. 2018 Dec;183(5):812-815. doi: 10.1111/bjh.15026. Epub 2017 Nov 16. No abstract available.


The Proteasome and Myeloma-Associated Bone Disease.

Accardi F, Toscani D, Costa F, Aversa F, Giuliani N.

Calcif Tissue Int. 2018 Feb;102(2):210-226. doi: 10.1007/s00223-017-0349-1. Epub 2017 Oct 28. Review.


Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.

Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, Vescovini R, Mancini C, Martella E, Campanini N, Schifano C, Bonomini S, Accardi F, Horenstein AL, Aversa F, Malavasi F, Giuliani N.

Oncotarget. 2017 May 16;8(34):56598-56611. doi: 10.18632/oncotarget.17896. eCollection 2017 Aug 22.


Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.

Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N.

Oncotarget. 2017 May 23;8(32):53053-53067. doi: 10.18632/oncotarget.18085. eCollection 2017 Aug 8.


IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N.

Haematologica. 2017 Apr;102(4):773-784. doi: 10.3324/haematol.2016.153841. Epub 2017 Jan 5.


The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma.

Giuliani N, Chiu M, Bolzoni M, Accardi F, Bianchi MG, Toscani D, Aversa F, Bussolati O.

Expert Opin Ther Targets. 2017 Mar;21(3):231-234. doi: 10.1080/14728222.2017.1279148. Epub 2017 Jan 18. No abstract available.


Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Horenstein AL, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V, Giuliani N, Malavasi F.

Mol Med. 2016 Dec;22:694-704. doi: 10.2119/molmed.2016.00198. Epub 2016 Oct 13.


Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N.

Blood. 2016 Aug 4;128(5):667-79. doi: 10.1182/blood-2016-01-690743. Epub 2016 Jun 6.


The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, Giuliani N.

Haematologica. 2016 Mar;101(3):e107-10. doi: 10.3324/haematol.2015.133736. Epub 2015 Dec 11. No abstract available.


Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N.

Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Epub 2015 Oct 22. Review.


The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.

Toscani D, Palumbo C, Dalla Palma B, Ferretti M, Bolzoni M, Marchica V, Sena P, Martella E, Mancini C, Ferri V, Costa F, Accardi F, Craviotto L, Aversa F, Giuliani N.

J Bone Miner Res. 2016 Apr;31(4):815-27. doi: 10.1002/jbmr.2741. Epub 2015 Dec 14.


NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.

Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, Marimpietri D, Bolzoni M, Toscani D, Oldham RJ, Cuccioloni M, Sasser AK, Pistoia V, Giuliani N, Malavasi F.

Cells. 2015 Sep 17;4(3):520-37. doi: 10.3390/cells4030520. Review.


The osteoblastic niche in the context of multiple myeloma.

Toscani D, Bolzoni M, Accardi F, Aversa F, Giuliani N.

Ann N Y Acad Sci. 2015 Jan;1335:45-62. doi: 10.1111/nyas.12578. Epub 2014 Nov 25. Review.


Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.

Manni S, Toscani D, Mandato E, Brancalion A, Quotti Tubi L, Macaccaro P, Cabrelle A, Adami F, Zambello R, Gurrieri C, Semenzato G, Giuliani N, Piazza F.

Leukemia. 2014 Oct;28(10):2094-7. doi: 10.1038/leu.2014.178. Epub 2014 Jun 4. No abstract available.


New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics.

Giuliani N, Lisignoli G, Magnani M, Racano C, Bolzoni M, Dalla Palma B, Spolzino A, Manferdini C, Abati C, Toscani D, Facchini A, Aversa F.

Stem Cells Int. 2013;2013:312501. doi: 10.1155/2013/312501. Epub 2013 May 23.


Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2013 Aug;27(8):1697-706. doi: 10.1038/leu.2013.24. Epub 2013 Jan 24.


Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.

Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2013 Apr;41(4):387-97.e1. doi: 10.1016/j.exphem.2012.11.005. Epub 2012 Nov 23.


Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F, Giuliani N.

Leukemia. 2013 Feb;27(2):451-63. doi: 10.1038/leu.2012.190. Epub 2012 Jul 11.


Supplemental Content

Loading ...
Support Center